Our previous studies indicated that PAK1 and PD-L1 expression might confer EGFR mutation-independent TKI resistance in NSCLC via persistent activation of PI3K/AKT and MEK/ERK signaling pathways [39, 40]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.